This, in turn, disrupts oncogenic MET receptor signaling induced by alterations in the MET gene, including MET exon 14 knockout mutations and MET protein overexpression, resulting in the death of tumor cells overexpressing MET protein or expressing constitutively activated MET protein.[4–6] Although several adverse effects of Capmatinib have been reported following clinical application, there is still a lack of comprehensive studies based on large databases. This evidence concerns the gene MET and neoplasm.